Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04071886
Other study ID # Second Xiangya hospital EMEN
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 1, 2019
Est. completion date January 2020

Study information

Verified date August 2019
Source Central South University
Contact Li Lingjiang, MD Ph.D
Phone +86 13807314575
Email LLJ2920@csu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to investigate the short-term effects of mindfulness-based training in individuals suffering from major depressive disorder (MDD) as assessed by clinical interviewing, self-report assessment, cognitive evaluation and eye-tracking task.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date January 2020
Est. primary completion date January 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria:

- Meet Diagnostic and Statistical Manual (DSM-IV) diagnosis of depression

- Consent to participate in the study and to be randomized to one of two groups

Exclusion Criteria:

- Current or past substance abuse, psychotic disorder,obsessive compulsive disorder , Post-Traumatic Stress Disorder, in the past 6 months

- History of epilepsy or head trauma

- Eye disorders

- History of electroconvulsive therapy in the past 4 weeks.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Mindfulness-Based Training
Mindfulness-Based Training comprises of mindful walking, body scanning and raisin meditation exercise. Participants will receive a guided session of mindfulness meditation, and will be asked to finish at least 30 minutes of Mindfulness-Based Training every day as homework as well as keep a diary describing their experiences and reflections. An expert in mindfulness practice will offer feedback and answer any questions online.
Relaxation Training
Participants will listen to a 15-minute Relaxation Training tape twice a day.

Locations

Country Name City State
China Mental Health Institute & Faculty of Psychiatry of The Second Xiangya Hospital, Central South University Changsha Hunan

Sponsors (1)

Lead Sponsor Collaborator
Central South University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean Change from Baseline in Eye Movement Performance During Free-View Task at 2 Weeks The first fixated location and latency (msec) of each trial, the total dwell time (msec) in each interest area (IA) during the whole trial to assess the attentional bias in the experiment. at baseline and in 2 weeks
Secondary Mean Change from Baseline in the Symptoms of Major Depression as Measured by BDI-II at 2 Weeks Measured by Beck Depression Inventory (BDI-II). BDI-II is a self-report questionnaire that measures the severity of depression on a scale of 0 to 63. Higher total scores indicate more severe depressive symptoms. at baseline and in 2 weeks
Secondary Mean Change from Baseline in the Symptoms of Major Depression as Measured by HAM-D at 2 Weeks Measured by Hamilton Rating Scale for Depression (HAM-D). HAM-D is used by clinicians to rate the severity of depression and to evaluate recovery. HAM-D score ranges from 0 to 51, with higher scores indicating more severe depressive symptoms. at baseline and in 2 weeks
Secondary Mean Change from Baseline in State Mindfulness at 2 Weeks Measured by the Five Facet Mindfulness Questionnaire (FFMQ). FFMQ measures five mindfulness skills through these subscales: Non-Reactivity to Inner Experience, Observing/Noticing, Acting With Awareness, Describing, and Non-Judging of Experience. The five subscale scores can be combined to yield a total score ranging from 0 to 195, measuring global mindfulness skills, with higher scores indicating higher level of global mindfulness skills. For FFMQ subscales, scores range from 8 to 40, except for Non-Reactivity to Experience scores, which range from 7 to 35. Higher subscale scores indicate higher level of respective mindfulness skills. at baseline and in 2 weeks
Secondary Mean Change from Baseline in Tendency to Engage in Ruminative Responses at 2 Weeks Measured by the Ruminative Responses Scale of the Response Styles Questionnaire (RRS). RRS measures the tendency to ruminate. RRS score ranges from 22 to 88, with higher scores indicate a stronger tendency to engage in ruminative thoughts. at baseline and in 2 weeks
See also
  Status Clinical Trial Phase
Completed NCT04482296 - Effect of Zinc Supplementation on Depression in SSRI-treated Major Depressive Disorder Patients N/A
Completed NCT04076644 - Maintenance Transcranial Magnetic Stimulation in Major Depressive Disorder N/A
Completed NCT05528315 - SAD/MAD of ABX-002-1902 Investigating the Safety, Pharmacokinetics/Pharmacodynamics of in Healthy Subjects Phase 1
Recruiting NCT05437588 - Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents N/A
Recruiting NCT06095778 - rTMS Therapy for Treatment-Resistant Depression With Different Targets Guided by pBFS N/A
Active, not recruiting NCT05657691 - Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition (XanaCIDD) Phase 2
Completed NCT02013609 - Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment Phase 3
Completed NCT02339285 - Transcranial Alternating Current Stimulation for Major Depressive Disorder N/A
Recruiting NCT03971305 - A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With Systemic ALK(+) ALCL
Recruiting NCT05169346 - Neurofeedback to Treat Depression N/A
Completed NCT01344733 - A Non Interventional Study to Investigating the Ratio of Mis-diagnosed Bipolar Symptoms in Patient With Major Depressive Disorder (MDD) N/A
Completed NCT04268316 - Virtual Reality Behavioral Activation: An Intervention for Major Depressive Disorder N/A
Active, not recruiting NCT01557946 - Glutamatergic and GABAergic Mediators of Antidepressant Response in Major Depression Phase 2
Recruiting NCT01501812 - Evaluation of Generalization Paradigm Patterns Among Different Psychiatric Disorders N/A
Completed NCT04880460 - Effect of Magnesium Supplementation in Selective Serotonin Reuptake Inhibitors Treated Major Depressive Disorder Patients Phase 2
Completed NCT04226352 - Three Dosing Regimens of Dextromethorphan (DXM) Reportedly Used in Major Depressive Disorder Phase 1
Recruiting NCT03754712 - Effect of Vitamin D Administration Along With SSRIs in Patients With Major Depressive Disorder N/A
Recruiting NCT02669030 - A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia Phase 4
Completed NCT03994081 - Mechanism of Action of tACS for the Treatment of MDD N/A
Completed NCT01152554 - A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder Phase 3